Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Pharmaxis Ltd.
The US biotech’s LOXL2 inhibitor candidate has reduced collagen fibrosis of the bone marrow in a small number of Phase II patients, helping validate a historically tricky approach attempted by few.
The Medtech Mandate, a scheme that seeks to better match NICE guidance with adoption and use of medtech innovations in the UK, is preparing for launch in April.
Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Two preclinical antibodies targeted at stromal biology-associated immuno-oncology processes from Canada’s Northern Biologics have been acquired by Boehringer Ingelheim, which is also to collaborate with Switzerland’s CDR-Life on the development of a preclinical antibody fragment aimed at geographic atrophy associated with age-related macular degeneration.
- In Vitro Diagnostics
- Medical Devices
- Drug Delivery
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Topigen Pharmaceuticals, Inc.